psilocybin low-dose / Relmada Therapeutics - LARVOL DELTA

Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD (EASL 2025) - "Adding low non-psychedelic doses of psilocybin to semaglutide further ameliorated insulin sensitivity and preserved muscle function in a mouse model of MASLD, paving the route for a possible combination therapy in MASLD patients with obesity, type 2 diabetes mellitus and sarcopenia."

Combination therapy • Diabetes • Genetic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Sarcopenia • Type 2 Diabetes Mellitus

Low nonpsychedelic dosed of psilocybin for the therapy of MASLD (EASL-ILC 2024) - "Low, nonpsychedelic doses of psilocybin significantly ameliorate MASLD features in experimental models, by a 5-HT2A mediated pleiotropic action. Psilocybin may be considered as a candidate drug for MASLD and associated metabolic disorders."

IO biomarker • Genetic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Mood Disorders • Obesity • Psychiatry • IR • PD-1

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023 (PRNewswire) - "'These initial animal data are quite compelling and warrant further evaluation in the clinic,' said Stephen Harrison...'There are currently no approved drugs for MASLD, and these initial pre-clinical results support the therapeutic potential of non-psychedelic/low dose psilocybin. Based on these data, non-psychedelic/low dose psilocybin could improve lipids and glucose with potential for fewer side effects over other investigative treatment approaches such as GLP-1, glucagon, and GIP. A significant opportunity exists to treat MASLD and associated metabolic disorders for a product with this profile'"

Media quote • Preclinical